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Abstract
Background—Limited epidemiological data exist about amyotrophic lateral sclerosis (ALS) in 
the United States (US). The Agency for Toxic Substances and Disease Registry maintains the 
National ALS Registry and funded state and metropolitan surveillance projects to obtain reliable, 
timely information about ALS in defined geographic areas.
Methods—Neurologists submitted case reports for ALS patients under their care between 
January 1, 2009 and December 31, 2011 who were New Jersey residents. A medical record 
verification form and electromyogram (EMG) report were requested for a sample of case reports. 
Incidence rates were standardized to the 2000 US Standard Population.
Results—The average crude annual incidence rate was 1.87 per 100,000 person-years, the 
average age-adjusted annual incidence rate was 1.67 per 100,000 person-years, and the point 
prevalence rate on December 31, 2011 was 4.40 per 100,000 persons. Average annual incidence 
rates and point prevalence rates were statistically higher for men compared with women; Whites 
compared with Blacks/African Americans and Asians; and non-Hispanics compared with 
Hispanics.
Conclusions—The project findings contribute new, population-based, state-specific information 
to epidemiological data regarding ALS. The findings are generally consistent with previously 
published surveillance studies conducted in the US and abroad.
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There are limited population-based epidemiologic data on amyotrophic lateral sclerosis 
(ALS) in the United States (US). Uncertainty about the incidence and prevalence of ALS, as 
well as limited information regarding its etiology, supports the need for a surveillance 
system for this disease [1]. The 2008 ALS Registry Act established the National ALS 
Registry (Registry), which is maintained by the federal Agency for Toxic Substances and 
Disease Registry (ATSDR). The Registry comprises individuals identified through the use 
of existing national administrative data sets (Medicare, Medicaid, Veteran’s Health 
Administration, and Veteran’s Benefit’s Administration) and patients who self-enroll 
through a secure web portal [2]. To evaluate the completeness of the Registry and to 
determine the incidence and prevalence of ALS in defined geographic areas, ATSDR 
developed three state-based (Florida, New Jersey, and Texas) and eight metropolitan area-
based (Atlanta, Baltimore, Chicago, Detroit, Las Vegas, Los Angeles, Philadelphia, and San 
Francisco) surveillance projects [2] .
ALS is a rare, progressive, fatal neurological disease affecting both the upper and lower 
motor neurons. Familial forms of ALS are thought to account for 5–10% of cases [3, 4], and 
other causes and risk factors are still under investigation, including environmental 
exposures, occupational exposures, physical activity and trauma, oxidative stress, and 
genetic factors [4-10]. There is no known cure for ALS.
A definitive clinical test for ALS does not exist, making the disease difficult to diagnose. 
ALS is diagnosed based on a combination of symptoms, signs and electromyography [11]. 
The El Escorial criteria use this information to determine possible, probable or definite ALS 
[11]. It has been demonstrated that using these criteria leads to very high agreement toward 
the presence of ALS between independent observers when applying the El Escorial criteria 
to patient charts [12]. The widespread adoption of these criteria by clinicians provides an 
opportunity for standardized case definition and case eligibility in research studies.
Much of the published literature describing ALS epidemiology is from outside of the US; 
not all studies provide age-adjusted rates, and case ascertainment methods are varied [13, 
14]. A systematic review of published literature regarding ALS from 1990 to 2004 reported 
that the median crude prevalence was 4.0 per 100,000 persons, the median crude incidence 
rate was 1.6 per 100,000 person-years (range = 0.7 to 2.5 per 100,000 person-years), a weak 
association with being a man, and a strong association with increased age [13]. A more 
recent systematic review of the population-based studies published worldwide from 1995 to 
2011 reported a higher median crude prevalence of 5.40 per 100,000 persons, a slightly 
higher median crude incidence rate of 2.08 per 100,000 person-years (range = 0.5 to 3.6 per 
100,000 person-years), and that incidence was the highest among those aged 60–75 [14]. A 
study of the European Registries confirmed a difference in incidences rates among men and 
women [15]. Evidence suggests that incidence rates and prevalence are lower among Blacks/
African-Americans compared to other races [16, 17]. Some US-based studies have also 
noted differences by age, sex, race, and ethnic subgroups, but these results should be 
interpreted cautiously as sample sizes were small [18-23] .
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The median duration of time from symptom onset to diagnosis has been reported to range 
from 9 to 11 months [24, 25]. The median survival from diagnosis ranges between 16.5 to 
23 months [25, 26] and most persons with ALS die within three years of diagnosis [26, 27] .
The objective of the New Jersey (NJ) ALS Surveillance Project was to gather reliable and 
timely data to better describe the incidence, prevalence and demographic characteristics of 
ALS among NJ residents.
Materials and Methods
Recruitment
This study was conducted in the state of NJ with a population of 8,791,894 persons in 2010 
[28]. Neurologists targeted for reporting included all neurologists practicing within the states 
of NJ and Delaware, two counties in New York, and the county of Philadelphia, Pa., as well 
as a targeted list of neurologists specializing in the diagnosis/treatment of ALS practicing in 
Allentown, Pa. and in the New York City region. Pediatric neurologists, neurosurgeons and 
medical residents were not actively recruited to participate. The neurologists were contacted 
via letters, phone calls, faxes and face-to-face site visits to determine if they diagnosed or 
provided care for ALS patients residing in NJ.
Data Collection
Neurologists who diagnosed or cared for ALS patients were asked to submit a one-page 
Case Reporting Form for each eligible patient. Eligible patients must have resided in NJ as 
per the address documented in the patient’s chart, had to be under the physician’s care at any 
time between January 1, 2009 and December 31, 2011, and had to fit into one of the El 
Escorial criteria classification levels [11]. The patients could have been diagnosed before 
2009. The Case Reporting Form included questions about patient demographic 
characteristics, including date of birth, sex, country of birth, race and ethnicity, all of which 
had predetermined response choices selected by the investigator. The response choice 
categories for the race question were as follows: ‘Asian,’ ‘Black/African American,’ 
‘White,’ ‘Unknown,’ and ‘Other’, with an option to specify ‘Other.’ The response choice 
categories for the ethnicity question were as follows: ‘Hispanic or Latino,’ ‘Non Hispanic or 
Latino,’ and ‘Unknown.’ The Case Reporting Form also included questions about month 
and year of symptom onset, month and year of diagnosis, El Escorial Criteria classification, 
and healthcare payer type.
Compensation was offered for each completed form. No patients were contacted. This 
project was approved by the Center for Disease Control and Prevention Institutional Review 
Board (IRB) and determined to be public health practice not requiring review, by the NJ 
Department of Health IRB.
To ensure the accuracy of diagnosis, a sample of 10–20% of reported cases was 
systematically selected for verification across all state and metropolitan projects. Case 
selection was weighted to review a greater proportion of cases submitted by small practices 
because of the concern for possible misdiagnosis among providers who rarely diagnose or 
treat ALS patients. A small practice was defined as one that said they diagnosed or provided 
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care to fewer than five ALS patients during the reporting period. The reporting provider was 
asked to complete a symptom-oriented Medical Record Verification Form for each selected 
case, and to attach an electromyogram (EMG) report from which patient identifying 
information, such as name, social security number, address and date of birth was redacted. 
The completed Medical Record Verification forms, along with copies of the redacted EMG 
reports, if available, were forwarded to the project’s consulting neurologist for independent 
assignment of El Escorial criteria classification.
NJ Department of Health death certificate data (2009–2011) and hospital discharge data 
(2009–2011) were evaluated to identify possible unreported cases of ALS. Death data were 
searched for International Classification of Diseases-10 code for motor neuron disease 
(G12.2) because ALS does not have its own specific code [29]. All certificates that 
explicitly listed a motor neuron disease other than ALS were excluded from follow-up 
activities. All certifying physicians for the non-reported decedents were contacted and asked 
if they could identify a neurologist of record for the decedents, and if so, that neurologist 
was contacted and an attempt was made to collect a case report. Similarly, hospital 
discharge data were searched for ALS diagnostic code 335.20 [30]. The records for non-
reported hospital patients were reviewed and when possible, a neurologist was contacted in 
an attempt to collect a case report. The attempts to procure case reports via review of death 
and hospital data are the second wave of data collection.
The 2009–2012 death data were queried to determine if reported cases died from any cause 
of death. Death certificate information was used to fill-in missing information and to resolve 
discrepancies between duplicate cases and then the dataset was de-duplicated. For cases 
reported more than one time, the case record with the most complete information was 
retained, scanned for missing information and the duplicate case reports were reviewed to 
fill in any missing information to create a composite, de-duplicated record.
Data Analysis
To calculate the average annual incidence for 2009, 2010 and 2011, all cases with a date of 
diagnosis before 2009 were excluded. To calculate the point prevalence as of December 31, 
2011, all cases with a known date of death in 2009, 2010 and 2011 were excluded. Crude 
and age-specific rates were calculated using the corresponding 2010 US Census population 
data as the denominator and are presented as cases per 100,000 persons [28]. Age-adjusted 
rates were standardized to the year 2000 US Standard Population [31] .
The time between symptom onset and diagnosis, as well as the survival time for cases 
known to be deceased as of December 31, 2012 were analyzed for incident cases diagnosed 
in 2009–2011. Fourteen cases missing a date of diagnosis and/or a date of symptom onset 
were removed. To calculate the time (in months) between the month and year of symptom 
onset and the month and year of diagnosis, the total number of months at symptom onset 
was subtracted from the total number of months at diagnosis (where total months = 
(Year*12)+Month). To calculate the time (in months) between the month and year of 
diagnosis and the month and year of death, the total number of months at diagnosis were 
subtracted from the total number of months at death. Data were analyzed using Microsoft 
Excel® (2010, Redman, Wash., USA) [32] and SPSS (v19.0, Armonk, N.Y., USA) [33] .
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Of the 679 neurologists in the region who were contacted, 168 (25%) diagnosed or cared for 
ALS patients in the reporting period; of these, 152 (90%) reported cases to the project. A 
physiatrist and generalist also reported cases, for a total of 154 reporting providers. Another 
160 (24%) neurologists did not diagnose or treat ALS patients in the reporting period, but 
stated they would check on an ALS patient if one presented to them for care. More than 50% 
(351/679) of the neurologists in the region did not diagnose or treat ALS patients.
Case Ascertainment
Based on a national ALS prevalence estimate of two cases per 100,000 persons and a 
survival of two and one-half years, the team expected to collect reports on about 700 
prevalent cases over three years in NJ’s population of nearly 8.8 million people [13, 28]. 
The team collected 963 case reports from the 154 reporting providers; 199 (21%) of these 
were duplicate cases reported by different practices, resulting in a total of 764 unique cases 
identified through active and follow-up case ascertainment.
Of the 764 unique cases identified, 697 cases were reported before reviewing the death 
certificate and hospital data. A review of the death certificate data yielded 209 possible ALS 
decedents and a review of hospitalization records resulted in 81 possible ALS patients who 
were unmatched to case reports. There were 39 names found in both data sets. Of the 251 
possible additional ALS cases, 67 were reported due to follow-up case ascertainment 
activities.
Case Validation
A total of 121 Medical Record Verification Forms were requested and 116 (96%) were 
received. After a review by the consulting neurologist, all 116 were found to be ALS.
Demographic Distribution of Cases
Of the 764 collected cases, 84% were over 50 years of age at diagnosis, 55.1% were male, 
83.2% were White, and 89.9% were non-Hispanic (table 1).
Incidence
A total of 493 cases were diagnosed between 2009 and 2011. The crude annual incidence 
rates for 2009, 2010, and 2011 were 1.77, 1.98, and 1.85 per 100,000 person-years, 
respectively, and the average crude annual incidence rate was 1.87 per 100,000 person-
years. Age-specific average annual incidence rates increased with age until age 70–79 (table 
2). After adjusting to the 2000 US Standard Population, the total age-adjusted average 
annual incidence rate was 1.67 per 100,000 person-years. Age-adjusted rates between males 
and females (1.96 vs. 1.42, respectively), between Whites and Asians (1.80 vs. 1.11, 
respectively), between Whites and Blacks (1.80 vs. 0.88, respectively), and between non-
Hispanics and Hispanics (1.66 vs. 0.93, respectively) were significantly different (table 3).
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Of the 764 cases, 327 died in 2009, 2010 or 2011 and 437 patients were alive on December 
31, 2011. The crude point prevalence as of December 31, 2011 was 4.97 per 100,000 
persons. Three cases were missing age at diagnosis and were removed, leaving 434 cases in 
the remaining prevalence-related analyses. The age-adjusted point prevalence overall was 
4.40 per 100,000 persons (table 4). Age-adjusted point prevalence rates between males and 
females (5.21 vs. 3.63, respectively), between Whites and Blacks (4.62 vs. 2.93, 
respectively) and between non-Hispanics and Hispanics (4.29 vs. 2.61, respectively) were 
significantly different (table 4).
Time from Symptom Onset to Diagnosis
Of 488 incident cases diagnosed in 2009–2011, the median age at diagnosis for these cases 
was 64 years (range: 19–90 years); 62 years for men and 66 years for women. The mean 
duration of time between symptom onset and diagnosis was 18 months, the median was 12 
months, and 90% of cases experienced symptoms up to 36 months before diagnosis (range: 
0–292 months) (table 5). The length of time between symptom onset and diagnosis was 
similar by age group, sex, race, and ethnicity.
Time from Diagnosis to Death
As of December 31, 2012, 53.1% (259/488) of incident cases diagnosed in 2009–2011 were 
known to be deceased. The median age at death for these cases was 70 years (range: 35–91 
years); 68 years for men and 72 years for women. The median survival from diagnosis was 
29 months. When the analyses were restricted to cases diagnosed in 2009 only, death 
certificates were retrieved for 64.3% (99/154) of these cases. The median age at death for 
these cases was 68 years (range: 35–91 years); 67 years for men and 70 years for women. 
The median survival from diagnosis was 21 months.
Discussion
Accurate estimates of incidence and prevalence of people affected by ALS in the US are 
needed by local, state, and federal health agencies, as well as patient services groups, and 
health care providers [1]. In the US, only a few studies provided epidemiological data for 
ALS; however, the study sites were small, defined geographic areas, the sample sizes were 
small, and not all studies relied on neurologists to report cases [18-23]. This report provides 
the first state-wide data on the incidence, prevalence, demographic characteristics, time from 
symptom onset to diagnosis, and time from diagnosis to death of ALS, based on a case 
ascertainment methodology among all neurologists, including neurologists specializing in 
the diagnosis/treatment of ALS at ALS specialty centers and neurologists in practice at 
general neurology practices.
There are two major metropolitan areas, New York City and Philadelphia, in close proximity 
to the NJ state border. Further, there are several ALS specialty centers located in New York, 
Pennsylvania, and Delaware that are a short distance from the NJ state border. With an 
understanding that NJ residents frequently seek health care beyond the state border, the 
outreach and recruitment strategy was broadened to include neurologists in parts of a four-
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state region. All neurologists in the region were recruited and encouraged to participate to 
have unbiased case ascertainment. We developed and sustained successful working 
relationships with reporting providers and their staff, particularly with specialty centers in 
the region that diagnose and care for ALS patients. These relationships were critical for 
collecting case reports, addressing data quality issues, and obtaining additional case reports 
for decedents and hospital patients. The patients’ willingness to travel and seek care from 
multiple providers warrants further research into health care seeking behaviors of ALS 
patients.
Although efforts were made to ensure that neurologists’ contact information remained 
accurate and current, it is possible that some neurologists may have moved into or out of the 
state, changed practices, or otherwise became unavailable to contact. Neurologists’ 
participation in this project was voluntary because ALS is not a mandatory reportable 
disease in NJ. We believe our recruitment efforts and compensation offers aided in the high 
participation rate of neurologists who diagnosed or treated eligible patients.
We were unsuccessful in recruiting a total of seven practices that stated neurologists or staff 
did diagnose or care for eligible ALS patients in the reporting period, including the two 
major Veterans Affairs Medical Centers in the region. The team was able to estimate that up 
to 50 cases went unreported because of their refusal to participate, but it is unclear how 
many of these cases may have been duplicates.
A total of 433 death certificates from 2009–2011 were identified and 224 (52%) of these 
decedents were reported to the project via active data collection. Up to 193 possible ALS 
cases identified in death and hospital discharge data were not reported. It is unclear how 
many of these possible cases were actually ALS. Finally, an estimated 3% of NJ residents 
die outside of NJ [34]; therefore, it is possible that some residents with ALS died outside NJ 
and their death certificates have not yet been transferred to NJ. Nevertheless, we are 
confident that a very large proportion of eligible cases were reported to the project and that 
very close to 100% of the death certificates were accounted for in our queries.
Incidence, prevalence, and demographic characteristics of reported ALS cases are similar to 
previously published findings in the United States and internationally [13-23]. After 
standardizing to the 2000 US Standard Population, we found significantly higher age-
adjusted average annual incidence rates among males compared with females, Whites 
compared with Asians, Whites compared with Blacks, and non-Hispanics compared with 
Hispanics. In addition, we found significantly higher age-adjusted point prevalence rates 
among males compared with females, Whites compared with Blacks, and non-Hispanics 
compared with Hispanics. Our findings with regard to sex differences are consistent with 
other published data that used a combination of case ascertainment methodologies such as 
established registries, case reports from neurologists and hospital billing data [13, 15]. The 
differences we found between non-Hispanic and Hispanic point prevalence rates are 
consistent with the only other published report of this type of ALS data that were collected 
in the United States (in parts of Texas) [19]. The results we found regarding the lower 
incidence rate among Blacks/African Americans is also consistent with the literature [16, 
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17]. We recommend that future studies examine racial differences among larger samples of 
the US population.
The median time from symptom onset to diagnosis for incidence cases diagnosed in 2009–
2011 was 12 months, which agrees with the findings of the previous research [15, 24, 25]. 
There were no or small differences between age groups, sexes, race groups and ethnic 
groups. Upon review of duplicate cases, the reported month and year of symptom onset and 
diagnosis sometimes varied between reporting providers. When creating composite records 
for cases reported more than one time, dates were retained from the same case report.
Case reports were collected for persons with ALS under the doctor’s care starting in 2009 
and those cases could have been diagnosed at any time before 2009. In order for the cases 
diagnosed before 2009 to appear as decedents in 2009–2012 mortality data, they may have 
had a longer period of survival compared to incident cases diagnosed in 2009–2001. In fact, 
the median survival for cases diagnosed before 2009 for which a death certificate was 
retrieved was 60 months. To avoid biasing our description of survival time toward this 
longer survival period, we restricted the analyses of time to death to incident cases 
diagnosed in 2009–2011 and those diagnosed in 2009 only. The median survival time 
diminished to 29 and 21 months, respectively, and these survival times are aligned with 
previously published findings [25-27]. However, these findings are subject to censorship, as 
the follow-up period ended on December 31, 2012, thus allowing only 12 months of follow-
up for cases diagnosed in December 2011. A future examination of death certificates beyond 
2012 will provide a richer dataset to characterize the survival of this cohort.
Conclusion
The results of this project provide the first state-wide data on age-adjusted incidence and 
prevalence of ALS. Conducting time-limited state-based surveillance for a non-reportable 
chronic condition was challenging, but with proper planning, adhering to data collection 
methodologies, providing compensation, and executing quality assurance procedures, 
project objectives were met. Our findings are generally consistent with other ALS 
surveillance studies in the United States and internationally.
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Table 1
Demographic characteristics of reported prevalent ALS cases in New Jersey, January 1, 2009 through 
December 31, 2011 (n = 764)
Demographic characteristic Count of cases % of cases
Age, years
 <30 7 0.9
  30–39 28 3.7
  40–49 87 11.4
  50–59 184 24.1
  60–69 210 27.5
  70–79 172 22.5
 ≥80 71 9.3
 Unknown 5 0.7
Sex
 Male 421 55.1
 Female 343 44.9
Race
 Asian alone 33 4.3
 Black alone 59 7.7
 White alone 636 83.2
 Other
a 7 0.9
 Unknown 29 3.8
Ethnicity
 Hispanic 44 5.8
 Non-Hispanic 687 89.9
 Unknown 33 4.3
Total 764 100.0
a
Includes one case with multiple races and any other race not specifically described in the table.
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Table 2
Age-specific average annual incidence rates for ALS cases diagnosed in three-year period 2009–2011 in New 
Jersey (n = 493)







≤30 4 3,385,581 0.04
 30–39 13 1,145,041 0.38
 40–49 40 1,354,434 0.98
 50–59 114 1,240,303 3.06
 60–69 143 831,514 5.73
 70–79 119 476,177 8.33
≥80 60 358,844 5.57
a
US Census Bureau (2011) [28].
b
Per 100,000 person-years.
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Table 3
Stratified age-adjusted average annual incidence rates for ALS cases diagnosed in three-year period 2009–
















 Male 265 4,279,600 1.96 1.72–2.20
 Female 228 4,512,294 1.42 1.23–1.60
Race
d
 Asian alone 22 725,726 1.11 0.62–1.60
 Black alone 31 1,204,826 0.88 0.57–1.20
 White alone 413 6,029,248 1.80 1.62–1.98
Ethnicity
d
 Hispanic 30 1,556,165 0.93 0.57–1.29
 Non-Hispanic 438 7,235,729 1.66 1.50–1.82
Total 493 8,791,894 1.67 1.52–1.82
a
US Census Bureau (2011) [28].
b
Age-adjusted to the year 2000 US Standard Population [31] and presented per 100,000 person-years.
c
Rates are statistically significant if the confidence intervals do not overlap.
d
Six cases with a race marked ‘Other’, 21 cases with an ‘Unknown’ race and 25 cases with an ‘Unknown’ ethnicity were excluded from this table.
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Table 4















 Male 242 4,279,600 5.21 4.54–5.88
 Female 192 4,512,294 3.63 3.11–4.15
Race
d
 Asian alone 24 725,726 3.37 1.95–4.80
 Black alone 35 1,204,826 2.93 1.94–3.92
 White alone 342 6,029,248 4.62 4.12–5.12
Ethnicity
d
 Hispanic 30 1,556,165 2.61 1.63–3.60
 Non-Hispanic 372 7,235,729 4.29 3.85–4.74
Total 434 8,791,894 4.40 3.98–4.82
a
US Census Bureau (2011) [29].
b
Age-adjusted to the year 2000 US Standard Population [31] and presented by 100,000 persons.
c
Rates are statistically significant if the confidence intervals do not overlap.
d
Five cases with a race marked ‘Other’, 28 cases with an ‘Unknown’ race and 32 cases with an ‘Unknown’ ethnicity were excluded from this table.
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Table 5
Time from symptom onset to diagnosis, stratified by age, sex, race, and ethnicity, for reported ALS cases 
diagnosed in three-year period 2009–2011 in New Jersey (n = 488)
Demographic
characteristics







Age at diagnosis, in years
 ≤30 4  16 27
 30–39 12  10 20
 40–49 40  10 29
 50–59 114  12 40
 60–69 141  12 29
 70–79 127  12 35
 ≤80 50  12 36
Sex
 Male 264  11 36
 Female 224  13 35
Race
a
 Asian alone 22  12 24
 Black alone 29  13 28
 White alone 410  12 36
Ethnicity
a
 Hispanic 30  9 26
 Non-Hispanic 433  12 35
Total
b 488  12 36
a
Information on 21 cases with a race marked ‘Other’, 6 cases with an ‘Unknown’ race; and 25 cases with an ‘Unknown’ ethnicity is not reported in 
this table.
b
Five cases with missing information for symptom onset and diagnosis were removed from the analyses of incident cases.
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